AOHC Encore 2023-221 Moderated Panel Introducing Pharmaceutical Digital Therapeutics (PDTs)

221 Moderated Panel Introducing Pharmaceutical Digital Therapeutics (PDTs)

Video Transcription

Video Summary

The video discussed prescription digital therapeutics (PDTs) as a new treatment class for substance use disorders, such as opioid addiction. The speakers, William Lacy, Terry Murphy, and Charles Yarborough, provided an overview of PDTs and their potential benefits for employers, patients, and prescribers. They explained that PDTs are software-based medical devices that have been approved by the FDA and can be used without direct medical supervision. The speakers emphasized that PDTs offer a potentially lower-cost and more effective alternative to traditional treatments for substance use disorders. They discussed the evolution of digital health and the challenges in adopting PDTs in the market. The speakers also shared a case study of the Teamsters Union and their successful implementation of PDTs for their truck drivers. They highlighted the privacy, flexibility, and accessibility of PDTs as advantages for patients. The video concluded with a Q&A session where the speakers addressed questions about PDT implementation, reimbursement, and the FDA approval process. Overall, the video provided an informative introduction to PDTs and their potential impact on substance use disorder treatment.

Keywords

prescription digital therapeutics

PDTs

substance use disorders

opioid addiction

FDA approval

software-based medical devices

lower-cost treatment

digital health

Teamsters Union